arrow
A

Abdullah Sakin

Medipol Bahcelievler Hospital
H指数:14
被引数:679

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma

avelumab维持治疗转移性尿路上皮癌的预后因素

2026-09-020
PRE
Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

晚期胸腺癌二线治疗的实际疗效:一项多中心土耳其肿瘤学组(TOG)研究

2026-08-270
OA
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis

围手术期FLOT方案后复发性胃和胃食管结合部癌的一线治疗:土耳其肿瘤学组(TOG)多中心真实世界分析

2026-05-180
PRE
Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective study

局部晚期直肠癌中总新辅助疗法的真实世界有效性:一项多中心回顾性研究

2026-03-230
OAAI
The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study

质子泵抑制剂对转移性非小细胞肺癌中纳武利尤单抗疗效的影响:一项多中心真实世界研究

2026-01-200
PRE
Long-Term Oncological Outcomes for Locally Advanced Rectal Cancer Patients with Pathological Complete Response After Neoadjuvant Chemoradiotherapy: A Turkish Oncology Group Study

局部晚期直肠癌患者新辅助化放疗后达到病理完全缓解的长期肿瘤学结局:土耳其肿瘤学组研究

2025-12-010
PRE
Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study

抗VEGF和抗EGFRs在微卫星不稳定(MSI-H)转移性结直肠癌中的疗效:土耳其肿瘤学组(TOG)队列研究

2025-11-180
OAAI
Real-world comparison of doxorubicin–ifosfamide versus gemcitabine–docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study

晚期子宫平滑肌肉瘤中多柔比星–异环磷酰胺与吉西他滨–多西他赛方案的真实世界比较:一项多中心回顾性研究

2025-11-170
OAAI
Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group

曲拉妥单抗(sacituzumab govitecan)在伴有转移性或局部晚期不可切除的三阴性乳腺癌患者中的真实世界有效性与安全性:土耳其肿瘤学组(Turkish Oncology Group)开展的一项多中心研究

2025-10-280
PRE
Efficacy and safety of doxorubicin–ifosfamide versus gemcitabine–docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world study

多中心真实世界研究:多柔比星–异环磷酰胺方案与吉西他滨–多西他赛方案作为一线疗法治疗晚期非子宫平滑肌肉瘤的疗效与安全性比较

2025-10-280
PRE
Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program

avelumab维持治疗在真实世界扩展性准入计划中的转移性尿路上皮癌患者中的应用

2025-10-160
PRE
Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer

吉西他滨联合白蛋白结合型紫杉醇二线治疗转移性胰腺癌的疗效观察

2025-04-050
OAAI
Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study

细胞周期蛋白依赖性激酶抑制剂后依维莫司加激素治疗的疗效; 现实生活经验,TOG研究

2024-08-090
PRE
Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer (vol 24, 16, 2024)
2024-01-230
OAAI
Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer
2024-01-022
OAAI
PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study
2023-11-014
PRE
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (vol 23, 136, 2023)

在CDK 4/6抑制剂治疗下疾病进展的激素阳性晚期乳腺癌患者中后续治疗的疗效 (第23卷,136,2023)

2023-02-272
OAAI
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

在CDK 4/6抑制剂治疗下疾病进展的激素阳性晚期乳腺癌患者的后续治疗效果

2023-02-1016
OAAI
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

晚期ALK阳性非小细胞肺癌患者一线阿来替尼治疗疗效和安全性的真实数据: 土耳其肿瘤学组研究

2022-06-231
PRE